脂蛋白a在心血管疾病中的研究进展  

Research progress of lipoprotein a in cardiovascular diseases

作　　者：吴硕 赵志豪 史宛鑫 迟晶[1] 王越红[1] WU Shuo;ZHAO Zhihao;SHI Wanxin;CHI Jing;WANG Yuehong(Department of Cardiology,The First Affiliated Hospital,Harbin Medical University,Harbin,150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院心内科,哈尔滨150001

出　　处：《临床心血管病杂志》2021年第12期1151-1156,共6页Journal of Clinical Cardiology

基　　金：国家自然科学基金资助项目(No:82000374、71531007);2020年度黑龙江省省属高等学校基本科研业务费科研项目(No:2020-KYYWF-1439)。

摘　　要：心血管疾病是全世界范围内引起死亡的主要原因,脂蛋白a[Lp(a)]升高与心血管疾病风险增加密切相关,是患动脉粥样硬化性心血管疾病及心血管死亡的独立危险因素。随着对Lp(a)升高危害性认识的不断加深,Lp(a)的降低治疗也越来越受到临床的关注。本文就Lp(a)的临床研究现状,及其作为心血管疾病风险预测因子的临床和遗传学证据及当前研究的不足进行综述。Cardiovascular disease is a major cause of worldwide death.Elevated lipoprotein a[Lp(a)]is closely associated with cardiovascular disease and is an independent risk factor for atherosclerotic cardiovascular disease and cardiovascular death.With the deepening understanding of the harm of elevated Lp(a),the treatment of reducing Lp(a)has received more and more clinical attention.The review summarizes the current status of clinical research on Lp(a),the clinical and genetic evidence as a predictor of cardiovascular disease risk,and the shortcomings of current research.

关 键 词：脂蛋白A 心血管疾病 动脉粥样硬化 降脂治疗 

分 类 号：R54[医药卫生—心血管疾病]